Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HCB301 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on HCB301, a putative anti-CD274 (PD-L1)/SIRPalpha/TGFbeta trap fusion protein (Apr 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HCB301 | HCB-301|HCB 301 | Limited information is currently available on HCB301, a putative anti-CD274 (PD-L1)/SIRPalpha/TGFbeta trap fusion protein (Apr 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06487624 | Phase I | HCB301 | An Engineered Sirpa Fused to Anti-Pd-L1 And Tgf-b Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors | Recruiting | USA | 0 |